Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 19, 2017
Pharmacy Choice - News - U.S. Pharmaceutical Industry - September 19, 2017

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

9/19/17 - 4D Molecular Therapeutics Receives $3 Million Follow-On Funding from Cystic Fibrosis Foundation Therapeutics for Gene Therapy IND Candidate for Cystic Fibrosis
4 D Molecular Therapeutics, a leader in adeno-associated virus gene therapy vector discovery and product development, today announced $3 million in additional funding from Cystic Fibrosis Foundation Therapeutics Inc., the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation, to expand ongoing efforts to develop an I
9/19/17 - 65 AXUMIN PET radiopharmaceutical used for PET imaging
Office Address: Department of Veterans Affairs; VA Sierra Pacific Network; VA Northern California HealthCare System; 5342 Dudley Blvd. Bldg 98; McClellan CA 95652-1012. Place of Performance: VA Palo Alto Healthcare System; 3801 Miranda Ave., Bldg. 100; Palo Alto, CA. Description: Department of Veterans Affairs.
9/19/17 - ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26, 2017
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September 26, 2017, at 10:00 a.m. Eastern Time i
9/19/17 - Acceleron Announces Proposed Public Offering of Common Stock
Acceleron Pharma Inc., a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare hematologic, neuromuscular, and pulmonary diseases, today announced that it intends to offer and sell, subject to market and other conditions, $150 million of its common stock in an underwritten public offer
9/19/17 - Acceleron Showcases Vision and Strategy at 2017 R&D Day
Acceleron Pharma Inc., a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, hosted its Research and Development Day in New York City today. The Company discussed clinical development plans to build therapeutic area leadership, and its long-term strategy to advance key prog
9/19/17 - Acceleron to Develop Sotatercept in Pulmonary Arterial Hypertension
Acceleron Pharma Inc., a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced it has amended the sotatercept development and commercialization collaboration agreement with Celgene Corporation, originally executed on February 20, 2008. Sotatercept shows...
9/19/17 - Achieve Announces Share Purchase Agreement with Lincoln Park Capital Fund, LLC
Release date- 18092017- BOTHELL, Wash. and VANCOUVER, British Columbia- Achieve Life Sciences, Inc., a clinical stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that it has entered into a share purchase agreement with Lincoln Park Capital Fund, LLC pursuant to
9/19/17 - Aclaris Therapeutics Announces Publication of Data from Phase 2 Clinical Trial of A-101 Topical Solution for Treatment of Facial Seborrheic Keratosis
Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company, today announced that results from a Phase 2 clinical trial evaluating two concentrations of its drug candidate A-101 for the treatment of facial seborrheic keratosis lesions have been published in the journal Dermatologic Surgery. The FDA s Prescription Drug User Fee Ac
9/19/17 - Agilent Announces Expanded Use of Cancer Diagnostic in the United States
Agilent Technologies Inc. today announced that the U.S. Food and Drug Administration has approved the cancer diagnostic known as PD-L1 IHC 28-8 pharmDx for use in cases of urothelial carcinoma and of squamous cell carcinoma of the head and neck. The PDL1 IHC 28-8 pharmDx test enables physicians in the USA to identify which patients with locally adv
9/19/17 - Agilent Announces Expanded Use of Cancer Diagnostic in the United States; .Dako PD-L1 IHC 28-8 PharmDx Approved for Two New Indications
SANTA CLARA, Calif. Agilent Technologies Inc. today announced that the U.S. Food and Drug Administration has approved the cancer diagnostic known as PD-L1 IHC 28-8 pharmDx for use in cases of urothelial carcinoma and of squamous cell carcinoma of the head and neck. The PDL1 IHC 28-8 pharmDx test enables physicians in the USA to identify which pat
9/19/17 - Agilent Obtains U.S. FDA Approval for GenetiSure Dx Postnatal Assay
SANTA CLARA, Calif.- Agilent Technologies Inc. has announced that it has obtained 510 clearance from the U.S. Food and Drug Administration for the GenetiSure Dx Postnatal Assay: its first comparative genomic hybridization assay for diagnostic use. Previously available only in Europe, U.S. clinical genetic scientists can now use this assay to help i
9/19/17 - Akari Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
Akari Therapeutics, an emerging growth, clinical-stage biopharmaceutical company, is pleased to announce its Chief Executive Officer Dr. David Horn Solomon and Chief Operations Officer Clive Richardson will present at the Cantor Fitzgerald Global Healthcare Conference on Tuesday September 26, 2017 in New York City. To access the live webcast of t
9/19/17 - Albireo to Present at Investor Conferences in September
Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present at the following investor conferences in September:. Cantor Fitzgerald Global Healthcare Conference Location: InterContinental New York Barclay in
9/19/17 - Aldeyra Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
Aldeyra Therapeutics, Inc., a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced the pricing of an underwritten public offering of 3,450,000 shares of its common stock at a public offering price of $7.25 per share.
9/19/17 - Alimera Sciences to Present at the Sidoti & Company Fall 2017 Conference
Alimera Sciences, Inc., a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, CEO, will present at the Sidoti& Company Fall 2017 Conference at the New York Marriott Marquis in New York, New York. Alimera Sciences presentation will take place Thursday, September 28th at 9:0
9/19/17 - American Renal Associates Holdings, Inc. Names Don E. Williamson, M.D. as Chief Operating Officer
American Renal Associates Holdings, Inc., a leading provider of outpatient dialysis services, today announced that it has named Don E. Williamson, M.D. as Executive Vice President and Chief Operating Officer effective today. Williamson has more than 26 years of experience as a nephrologist, and he most recently served as President, CEO and Managing
9/19/17 - AMICUS THERAPEUTICS INC FILES (8-K) Disclosing Other Events, Financial Statements and Exhibits
On September 19, 2017, Amicus Therapeutics, Inc. issued a press release announcing that the U.S. FDA has granted Fast Track Designation for Amicus Therapeutics' Migalastat for Treatment of Fabry Disease. A copy of this press release is attached hereto as Exhibit 99.1. Description 99.1 Press Release dated September 19, 2017 titled " U.S. FDA Grants
9/19/17 - Amylyx Pharmaceuticals Receives FDA Orphan Drug Designation for AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis
Amylyx Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration has granted orphan drug designation to AMX0035, an oral therapeutic in clinical development for the treatment of amyotrophic lateral sclerosis. The Company recently began a Phase 2 clinical study, the CENTAUR trial, to evaluate the safety and efficacy of AMX003
9/19/17 - Archway Examines the Impact of Bundled Payments Ahead of Expected New CMS Programs
According to a survey conducted by Archway Health a Boston- based firm specializing in managing bundled payments programs participation in bundled payments has improved the quality of care, and anticipation and preparation for new programs remains high. The survey assessed the perceptions and efficacy of bundled payments ahead of the expected
9/19/17 - Argos Therapeutics to Hold Conference Call to Discuss Update on the Phase 3 ADAPT Trial Presented at the ESMO 2017 Congress
Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis precision immunotherapy technology platform, will hold a conference call to discuss an update on the ongoing Phase 3 ADAPT clinical trial evaluating Rocapuldencel-T for the treatment of...
9/19/17 - Arkis BioSciences Achieves FDA Clearance of its CerebroFlo? EVD Catheter with Endexo Technology
Arkis BioSciences, a leading innovator in minimally invasive surgical instrumentation, has obtained FDA clearance of its new external ventricular drainage catheter, CerebroFlo?. Seaver says Arkis plans to introduce the device to the U.S. market at the upcoming annual Congress of Neurological Surgeons, which will be held in Boston, MA, Oct. 7-11
9/19/17 - ArQule to Present at the Cantor Fitzgerald Global Healthcare Conference on September 26, 2017
ArQule, Inc. today announced that Paolo Pucci, Chief Executive Officer, and Dr. ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. Our clinical-stage pipeline consists of five drug candidates, all of which are in targeted, biomarker-defined patient populations,
9/19/17 - Atossa Genetics, Endoxifen Phase I Results and Pipeline Review
NEW YORK, NY/ ACCESSWIRE/ September 19, 2017/ Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies, is issuing a comprehensive report with no obligation on Atossa Genetics Inc., a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to
9/19/17 - Attorney General Herring Calls for Continued Commitment to Opioid Crisis, Outlines Priorities
Virginia Attorney General Mark R. Herring issued the following news release:. During remarks in Virginia Beach before the Virginia Association of Chiefs of Police annual conference, Attorney General Mark R. Herring outlined his recommended next steps for the Commonwealth of Virginia as we continue to confront the national epidemic of opioid and her
9/19/17 - Australian-First Personalised Medicine Clinical Trial for Children With Most Aggressive Cancers
The University of New South Wales issued the following news release:. Zero Childhood Cancer, one of the world's most comprehensive child cancer personalised medicine studies, has been launched by Children's Cancer Institute and the Kids Cancer Centre at Sydney Children's Hospital, Randwick. In an Australian first, scientists from 13 leading Austral
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415